Results 81 to 90 of about 15,012 (140)
Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence. [PDF]
Ther Adv HematolMohammed Saleh MF +7 more
europepmc +1 more source
Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial. [PDF]
J Hematol OncolWu R +19 more
europepmc +1 more source
B cell-driven refractory hemocytopenia in immune checkpoint inhibitor therapy: a report of two cases. [PDF]
Transl Lung Cancer ResLi F +6 more
europepmc +1 more source
A Case of Cerebral Venous Sinus Thrombosis Following Eltrombopag in Immune Thrombocytopenia. [PDF]
CureusRaja T +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Growth Factors, 1999
Thrombopoietin (TPO) was first described as an activity in thrombocytopenic serum that could stimulate platelet production upon transfer into other animals. The molecular cloning of TPO has allowed a detailed characterisation of its precise biological activities, both in vitro and in vivo.
C R, Underhill, R L, Basser
openaire +4 more sources
Thrombopoietin (TPO) was first described as an activity in thrombocytopenic serum that could stimulate platelet production upon transfer into other animals. The molecular cloning of TPO has allowed a detailed characterisation of its precise biological activities, both in vitro and in vivo.
C R, Underhill, R L, Basser
openaire +4 more sources
Transfusion Science, 1997
The term "thrombopoietin" (TPO) was first coined in 1958 but, despite several cytokines having thrombopoietic effects, the major megakaryocytic growth and development factor was not cloned until 1994. Wendling and colleagues (Virol, 1986; 149: 242-246) recognised a novel murine viral oncogene, v-mpl, responsible for a myeloproliferative syndrome.
openaire +4 more sources
The term "thrombopoietin" (TPO) was first coined in 1958 but, despite several cytokines having thrombopoietic effects, the major megakaryocytic growth and development factor was not cloned until 1994. Wendling and colleagues (Virol, 1986; 149: 242-246) recognised a novel murine viral oncogene, v-mpl, responsible for a myeloproliferative syndrome.
openaire +4 more sources
Current Opinion in Pediatrics, 1998
Thrombopoietin is a hematopoietic growth factor that stimulates megakaryopoiesis. Recent results indicate that thrombopoietin has multilineage hematopoietic effects both in vitro and in vivo. Clinical studies of thrombopoietin have begun, and are reviewed.
V C, Broudy, K, Kaushansky
openaire +2 more sources
Thrombopoietin is a hematopoietic growth factor that stimulates megakaryopoiesis. Recent results indicate that thrombopoietin has multilineage hematopoietic effects both in vitro and in vivo. Clinical studies of thrombopoietin have begun, and are reviewed.
V C, Broudy, K, Kaushansky
openaire +2 more sources
Immunology Letters, 1998
The extracellular domain of human c-Mpl, the receptor for thrombopoietin (TPO), was expressed as a chimeric protein with the interleukin-2 receptor alpha chain on the surface of murine B cell-line B300-19. BALB/c mice were immunized with cells expressing the chimeric protein.
M, Abe +8 more
openaire +2 more sources
The extracellular domain of human c-Mpl, the receptor for thrombopoietin (TPO), was expressed as a chimeric protein with the interleukin-2 receptor alpha chain on the surface of murine B cell-line B300-19. BALB/c mice were immunized with cells expressing the chimeric protein.
M, Abe +8 more
openaire +2 more sources